ADF, novel cytokine PPAR-gamma regulator from fat cells

ADF，来自脂肪细胞的新型细胞因子 PPAR-gamma 调节剂

• 批准号: 6337789
• 负责人: DAVID S LEVIN
• 金额: $ 10万
• 依托单位: GENETEX, INC.
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-09-30 至 2003-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6337789
• 关键词: adipocytes; cell differentiation; cytokine; genetic library; growth factor; molecular cloning; obesity; peroxisome proliferator activated receptor; polymerase chain reaction; protein purification; synthetic peptide

DESCRIPTION (Scanned from the Applicant's Abstract): Obesity is a major risk factor for diabetes mellitus (type 2; NIDDM). Fat cells secrete both diabetes promoting molecules (fatty acids; TNF-alpha) and at least one molecule that may be antidiabetic (leptin). We have partially purified a new protein (cytokine) which is also secreted by mature adipocytes, Adipocyte Differentiation Factor (ADF). We hypothesize that ADF may have antidiabetic action, since, like the antidiabetic thiazolidinedione drugs, it induces fat cell differentiation and is a positive regulator for genes involved in the control of adipose cell proliferation and glucose metabolism. One of these genes is the nuclear transcription factor PPAR-gamma. This important regulator of adipose cell differentiation is now increasingly recognized as involved in numerous metabolic pathways and neoplasms. PPAR-gamma is activated in vivo and in culture by the thiazolidinedione class of drugs, now widely used as therapeutic agents in diabetes and experimentally in certain human cancers. However, the physiologic regulation of PPAR-gamma itself is not understood. ADF initiates very rapid fat cell differentiation and increases PPAR-gamma mRNA and protein levels. The purification of ADF will permit the development of assays for use in understanding the physiology of ADF and to develop treatments for obesity, diabetes, and other diseases in which PPAR-gamma proves to play a key role. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

描述(摘自申请者的摘要)：肥胖是一个主要风险 糖尿病因素(2型；NIDDM)。脂肪细胞分泌这两种糖尿病 促进分子(脂肪酸；肿瘤坏死因子-α)和至少一个可能 抗糖尿病(瘦素)。我们已经部分提纯了一种新的蛋白质(细胞因子) 它也由成熟脂肪细胞分泌，脂肪细胞分化因子 (ADF)。我们假设ADF可能有抗糖尿病作用，因为，像 抗糖尿病药物，它诱导脂肪细胞分化和 是参与脂肪细胞控制的基因的正向调节因子 增殖和葡萄糖代谢。其中一个基因是核 转录因子PPAR-γ。脂肪细胞的重要调节因子 差异化现在越来越多地被认为涉及到许多 代谢途径和肿瘤。PPAR-γ在体内和体内被激活 培养所用的噻唑烷二酮类药物，现在被广泛用作治疗 治疗糖尿病和某些人类癌症的试验性药物。然而， PPAR-伽马本身的生理调节尚不清楚。ADF启动 脂肪细胞快速分化并增加PPAR-γ的mRNA和蛋白 级别。ADF的提纯将允许开发用于分析的方法 在了解ADF的生理学和开发肥胖症的治疗方法方面， 糖尿病和其他疾病，在这些疾病中，PPAR-Gamma被证明发挥了关键作用。 建议的商业应用：不可用